Effect of DUOLXETINE in central post-stroke pai

Not Applicable

Completed

• Conditions: Health Condition 1: G890- Central pain syndrome

• Registration Number: CTRI/2021/03/031875
• Lead Sponsor: INSTITUE OF MEDICAL SCIENCES BH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-02-28
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 82

Inclusion Criteria

�Aged 18 years or older

�Positive history of hemorrhagic or ischemic stroke with lesion in the unilateral brain region proved by computed tomography or magnetic resonance imaging of the brain

�Presence of signs and symptoms in accordance with a decrease in pain and heat sensations in the affected part of the body

�Presence of spontaneous or stimulated pain in the affected side, which could be smaller or the same in size as the sensory impairment area, fulfilling the mandatory criteria proposed by Klit et al.

�Patients with moderate to severe pain (Numeric Rating Scale (NRS) score of 4 and higher) are included.

� Patients who are already on any other drugs for CPSP can be included in the study after providing a washout period of two weeks

�Only first episode stroke patients to be taken in the study.

Exclusion Criteria

�Not willing to participate in the study

�Lack of imaging findings compatible with stroke (like tumors)

�Likely peripheral causes of pain (pain due to spasticity, nociceptive, psychogenic causes)

�Hypersensitivity to duloxetine

�Previous treatment with SNRIs

�Pregnant or lactating women

Study & Design

• Study Type: Interventional
• Study Design: Not specified